Illumina, Inc. (NASDAQ:ILMN) Given Average Recommendation of “Hold” by Brokerages

Shares of Illumina, Inc. (NASDAQ:ILMN) have been assigned a consensus recommendation of “Hold” from the eighteen ratings firms that are covering the company, Marketbeat reports. Two analysts have rated the stock with a sell rating, nine have given a hold rating and seven have issued a buy rating on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $138.3750.

A number of research firms have commented on ILMN. Royal Bank Of Canada began coverage on shares of Illumina in a report on Thursday, May 14th. They issued an “outperform” rating and a $170.00 price objective for the company. Weiss Ratings downgraded shares of Illumina from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, April 29th. Guggenheim increased their price objective on shares of Illumina from $170.00 to $180.00 and gave the company a “buy” rating in a report on Monday. Wall Street Zen downgraded shares of Illumina from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Finally, Evercore restated an “outperform” rating on shares of Illumina in a report on Friday, May 1st.

More Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Guggenheim raised its price target on Illumina to $180 from $170 and reiterated a Buy rating, reflecting optimism about clinical sequencing momentum, consumables pricing, and the company’s pipeline. Article
• Positive Sentiment: Integrated DNA Technologies expanded its collaboration with Illumina, linking xGen FFPE and cfDNA workflows to DRAGEN and Connected Insights, which could deepen Illumina’s role in oncology research and support software adoption. Article
• Positive Sentiment: Recent commentary highlighted Illumina’s better execution, stronger NovaSeq X adoption, and higher full-year 2026 guidance, which has helped extend the stock’s rally. Article
• Neutral Sentiment: Illumina reported small insider sales, including a routine Rule 10b5-1 sale by the chief accounting officer, which is not unusual but adds to scrutiny around insider activity. SEC filing
• Negative Sentiment: Director Keith A. Meister sold a large block of shares in multiple transactions, which could weigh on sentiment despite no direct sign of operational weakness. SEC filing

Illumina Stock Up 5.2%

ILMN stock opened at $170.93 on Thursday. The company has a market cap of $25.86 billion, a price-to-earnings ratio of 31.08, a PEG ratio of 2.69 and a beta of 1.50. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. Illumina has a 12 month low of $81.75 and a 12 month high of $172.49. The firm has a 50-day moving average of $136.19 and a two-hundred day moving average of $133.03.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. The company had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. Illumina’s quarterly revenue was up 4.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, analysts forecast that Illumina will post 5.2 earnings per share for the current fiscal year.

Insider Activity

In other news, SVP Christensen Jakob Wedel sold 700 shares of the firm’s stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total transaction of $97,328.00. Following the completion of the sale, the senior vice president owned 15,056 shares in the company, valued at $2,093,386.24. This trade represents a 4.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Scott D. Ericksen sold 500 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $160.00, for a total transaction of $80,000.00. Following the sale, the chief accounting officer owned 14,446 shares of the company’s stock, valued at $2,311,360. This represents a 3.35% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,002,371 shares of company stock worth $155,472,900 over the last quarter. 2.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Illumina

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Capital World Investors increased its holdings in shares of Illumina by 0.6% during the 4th quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company’s stock worth $2,636,483,000 after buying an additional 124,323 shares during the last quarter. State Street Corp increased its holdings in shares of Illumina by 3.2% during the 4th quarter. State Street Corp now owns 6,190,114 shares of the life sciences company’s stock worth $811,895,000 after buying an additional 190,324 shares during the last quarter. WCM Investment Management LLC increased its holdings in shares of Illumina by 45.5% during the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after buying an additional 1,851,848 shares during the last quarter. AQR Capital Management LLC boosted its position in shares of Illumina by 30.3% during the 4th quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock worth $580,531,000 after purchasing an additional 1,028,099 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of Illumina by 4.8% during the 4th quarter. Geode Capital Management LLC now owns 2,869,047 shares of the life sciences company’s stock worth $375,260,000 after purchasing an additional 130,139 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.